Stoke Therapeutics, Inc. (STOK) Profit Margins
Over the twelve months to 2026-06-30, Stoke Therapeutics, Inc. (STOK) had operating margin -809.7%, net margin -753.6%, free cash flow margin -654.9%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STOKStoke Therapeutics, Inc.Follow STOK — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating margin | -841.2% | -1307.2% | -277.3% | -11.2% | -809.7% | |
| Net margin | -814.7% | -1192.5% | -243.4% | -3.7% | -753.6% | |
| FCF margin | -288.8% | -941.7% | -238.1% | 24.4% | -654.9% |
USD millions · SEC XBRL
Stoke Therapeutics, Inc. — questions
- What is Stoke Therapeutics, Inc.'s operating margin?
- -809.7% over the twelve months to 2026-06-30.
- What is Stoke Therapeutics, Inc.'s net profit margin?
- -753.6% over the twelve months to 2026-06-30.
Every figure on this page comes from Stoke Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.